0 COVID-19 antibody assay can analyze up to 40,000 samples daily
LGC (Cambridge, UK) has developed a COVID-19 antibody assay that can analyze up to 40,000 samples daily and is suitable for…
Browsing: News
0 New antibody test for SARS-CoV-2
A new SARS-CoV-2 antibody test has been developed with improved accuracy and higher sample throughput at a lower cost in…
0 In Focus: studying the COVID-19 pandemic – a Special Focus Issue
Infectious Diseases Hub has partnered with Future Virology to bring you exclusive access to articles and features in the recent Special Focus Issue.
0 AstraZeneca COVID-19 vaccine trial resumed in the UK after safety evaluation
AstraZeneca and Oxford University (UK) have resumed the progress of their Phase III COVID-19 vaccine trial after investigating unexpected side effects in a patient enrolled in the trial in the UK.
0 Cytokine storm could sabotage long-term immunity against SARS-CoV-2
COVID-19 patients who develop a cytokine storm in response to infection could be unable to produce memory cells that provide long-term protection against SARS-CoV-2.
0 Countries with previous TB vaccine coverage show improved COVID-19 outcomes
An epidemiological study has revealed that COVID-19 outcomes are better in those countries that have undertaken a TB vaccination regime in the last 15 years.
0 Asymptomatic COVID-19 patients still carry the same amount of virus
A study undertaken in South Korea has shown that the viral load in asymptomatic COVID-19 patients is the same as in those who show symptoms of the disease and this could be contributing to the spread of the infection in populations.
0 Malaria parasites resistant to artemisinin now prevalent in Africa
Malara parasites showing artemisinin resistance previously seen in South-East Asia have recently emerged in areas of Rwanda in Sub-Saharan Africa. If the mutation causing resistance becomes prevalent across the continent it could have major public health impacts.
0 Oxford vaccine gives strong immune response against COVID-19
The Oxford vaccine, ChAdOx1 nCoV-19, has demonstrated strong immune responses to COVID-19 in patients, as well as a good safety profile, as the results of the Phase I/II trial are published.
0 COVID-19: success seen in Synairgen inhalable drug trial
In collaboration with the University of Southampton, Synairgen (both Southampton, UK) have announced positive results from their recent trial of SNG001, a novel protein based COVID-19 drug.
